In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

ANI Pharmaceuticals has commenced a Phase IV trial to compare two dosage levels of Purified Cortrophin Gel for acute gout ...

Medicus Pharma has announced the commencement of the Phase II SKNJCT-004 trial for non-invasive treatment of BCC of the skin.

Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...

At CTO West Coast, an expert discussed the implications of the FDA’s expedited approval programmes with a spotlight on ...

Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial.

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.

Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...

AnnJi Pharmaceutical has reported encouraging outcomes from its randomised, placebo-controlled Phase I/IIa trial of AJ201.

Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.